Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03158142 · ClinicalTrials.gov registry record · Phase 4

The Influence of Atropine on Choroidal Thickness

A Phase 4 study of Myopia, sponsored by State University of New York College of Optometry.

Completed
Registry status
Phase 4
Development phase
32
Enrollment target
1
Study location

NCT03158142 is a Phase 4 study of Myopia that has completed, run by State University of New York College of Optometry. The registered enrollment target is 32 participants, below the 268-participant average among 90 other Myopia trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03158142, a Phase 4 study of Myopia, has completed, sponsored by State University of New York College of Optometry.

COMPLETED
Registry status
Phase 4
Development phase
32 participants
Enrollment target
1
Study location

Study Summary

Atropine eye drops are increasingly prescribed for the management of progressive myopia or short-sightedness. A previous study suggested that the back of the eye or choroid may be a part of the mechanism by which it induces its effects. The aim of this study is to characterize the effects of atropine on choroidal thickness and the influence of time of administration (am vs pm). It is hypothesized that the atropine's effect on choroidal thickness will vary with baseline thickness related to diurnal rhythm, where thicker baseline thickness will show a reduced choroidal response.

Conditions Studied

Interventions

  • DRUG Atropine Sulfate 1% Oph Soln

Study Locations (1)

New York

  • State University of New York College of Optometry - New York

Trial Details

FieldValue
Enrollment Target 32 participants
Start Date 2017-03-15
Est. Completion 2017-11-20
Phase Phase 4

What the Registry Record Tells You About NCT03158142

The ClinicalTrials.gov registry entry for NCT03158142 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 268-participant average among 90 other Myopia trials with a reported enrollment target (88% lower). The listed sponsor is State University of New York College of Optometry, which has 14 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Myopia appearing as the primary indexed condition, and to 1 intervention - of which Atropine Sulfate 1% Oph Soln is the first listed.

NCT03158142 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT03158142 about?

NCT03158142 is a clinical study titled "The Influence of Atropine on Choroidal Thickness". Atropine eye drops are increasingly prescribed for the management of progressive myopia or short-sightedness. A previous study suggested that the back of the eye or choroid may be a part of the mechanism by which it induces its effects. The aim of this study is to characterize the effects of atropi...

What is the current status of trial NCT03158142?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 32 participants. The study started on 2017-03-15. Estimated completion is 2017-11-20.

What conditions does trial NCT03158142 study?

This clinical trial studies the following conditions: Myopia.

What interventions are being tested in trial NCT03158142?

The interventions under investigation include: Atropine Sulfate 1% Oph Soln (DRUG).

Who is sponsoring clinical trial NCT03158142?

This trial is sponsored by State University of New York College of Optometry, which has 14 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03158142 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Myopia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.